Mid-stage data reported at the ESMO congress in Barcelona showed that ... It involved 187 patients with cachexia associated with lung, pancreatic, or colorectal cancer. After 12 weeks of treatment ...

2024 Metabolic-Bariatric Surgery Reduces Pancreatic Cancer Risk Effect appeared more pronounced among those with type 2 diabetes. Medscape Medical News, October 11, 2024 ESMO 2024 TDXd Better Than ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Despite advancements in treatments for various cancers, pancreatic cancer remains a significant challenge, with the NHS acknowledging that it "can be difficult to treat". Early diagnosis is vital ...

Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...

This include BTC, head and neck cancer and pancreatic cancer ... Based on the data Bob mentioned that was released at ESMO that I will speak more to it in a moment, we are excited to and are ...

Immunocore reports third quarter financial results and provides a business updateKIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q ...

Welcome to the NovoCure Q3 2024 earnings conference call. [Operator instructions] Please be advised that today's conference ...

AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...

Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC ...